Guided Therapeutics (GTHP) Liabilities and Shareholders Equity (2010 - 2025)

Guided Therapeutics has disclosed Liabilities and Shareholders Equity across 16 years of filings, most recently posting $1.3 million for Q4 2025.

• Liabilities and Shareholders Equity for Q4 2025 came in at $1.3 million, down 3.92% year-over-year; the trailing twelve-month figure through Dec 2025 was $4.1 million (down 23.05% YoY), and the FY2025 annual result was $1.3 million, down 3.92% from the prior year.
• Liabilities and Shareholders Equity came in at $1.3 million for Q4 2025 at Guided Therapeutics, up from $903000.0 in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $3.9 million in Q3 2022 to a low of $903000.0 in Q3 2025.
• The 5-year median for Liabilities and Shareholders Equity is $1.7 million (2021), against an average of $1.9 million.
• Across the five-year window, Liabilities and Shareholders Equity soared 548.9% in 2021 and sank 51.51% in 2023, its largest moves.
• Guided Therapeutics' Liabilities and Shareholders Equity stood at $2.0 million in 2021, then jumped by 65.0% to $3.4 million in 2022, then sank by 50.42% to $1.7 million in 2023, then fell by 17.44% to $1.4 million in 2024, then declined by 3.92% to $1.3 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $1.3 million (Q4 2025), $903000.0 (Q3 2025), and $940000.0 (Q2 2025), per Business Quant data.